RLAY

+ Watchlist + Portfolio

Relay Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.49
52-Week Range: $5.47 – $21.27
Market Cap: $4.15B
P/E (TTM): —
EPS (TTM): -1.56
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.66
PEG Ratio: —
Return on Equity: -36.77%
Return on Assets: -22.88%
Gross Margin: 0.00%
Operating Margin: -25949.72%
Profit Margin: 0.00%
Current Ratio: 18.27
Debt/Equity: 0.03
Total Debt: $30.66M
Free Cash Flow: $-119.24M
Revenue Growth: -48.30%
Earnings Growth: —
Enterprise Value: $3.27B

RLAY Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.38M	$25.55M	$10.01M	$15.36M
Research & Development	$246.35M	$330.02M	$319.09M	$261.38M
Selling, General & Admin	$65.98M	$74.95M	$76.59M	$56.71M
Operating Expenses	$312.33M	$404.97M	$395.68M	$318.09M
Operating Income	-$310.95M	-$379.42M	-$385.67M	-$302.74M
EBITDA	-$306.82M	-$374.15M	-$380.21M	-$299.18M
Pretax Income	-$290.51M	-$341.97M	-$337.71M	-$276.48M
Net Income	-$290.51M	-$341.97M	-$337.71M	-$276.48M
Diluted EPS	-2.59	-2.79	-2.36	-1.61
Diluted Shares	112.23M	122.58M	142.87M	171.59M

RLAY Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$151.79M	$143.74M	$124.29M	$84.02M
Receivables	$5.22M	$0.00	—	—
Current Assets	$1.02B	$770.10M	$809.20M	$578.28M
Total Assets	$1.10B	$843.98M	$871.30M	$621.33M
Current Liabilities	$63.71M	$30.27M	$50.73M	$25.58M
Total Debt	$57.74M	$53.47M	$48.50M	$32.46M
Total Liabilities	$149.55M	$91.98M	$93.50M	$54.27M
Retained Earnings	-$1.06B	-$1.40B	-$1.74B	-$2.01B
Shareholders' Equity	$950.22M	$752.00M	$777.79M	$567.06M
Working Capital	$955.80M	$739.83M	$758.48M	$552.70M

RLAY Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$229.49M	-$300.32M	-$249.11M	-$235.46M
Capital Expenditure	-$9.06M	-$4.13M	-$2.02M	-$410.00K
Free Cash Flow	-$238.55M	-$304.44M	-$251.13M	-$235.87M
Depreciation & Amortisation	$4.13M	$5.27M	$5.46M	$3.56M
Stock-Based Compensation	$56.14M	$86.03M	$94.14M	$62.42M
Investing Cash Flow	-$188.75M	$257.63M	-$41.08M	$192.80M
Financing Cash Flow	$289.91M	$34.75M	$270.15M	$1.60M
Net Change in Cash	-$128.32M	-$7.93M	-$20.04M	-$41.05M

RLAY Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$7.68M	$677.00K	$0.00	$7.00M	$3.00M	$350.00K
Research & Development	$73.81M	$63.90M	$68.26M	$55.41M	$70.56M	$76.48M
Selling, General & Admin	$18.74M	$13.63M	$12.13M	$12.21M	$11.03M	$14.69M
Operating Expenses	$92.55M	$77.52M	$80.39M	$67.63M	$81.59M	$91.17M
Operating Income	-$84.87M	-$76.85M	-$80.39M	-$60.63M	-$78.59M	-$90.82M
EBITDA	-$83.66M	-$75.84M	-$79.64M	-$60.03M	-$78.09M	-$90.46M
Pretax Income	-$77.06M	-$70.38M	-$74.15M	-$54.89M	-$73.29M	-$83.71M
Net Income	-$77.06M	-$70.38M	-$74.15M	-$54.89M	-$73.29M	-$83.71M
Diluted EPS	-0.46	-0.41	-0.43	-0.32	-0.41	-0.41
Diluted Shares	169.23M	171.26M	172.39M	173.40M	179.85M	202.85M

RLAY Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$93.54M	$113.94M	$91.56M	$84.02M	$204.59M	$121.19M
Current Assets	$739.66M	$680.39M	$624.01M	$578.28M	$658.46M	$928.08M
Total Assets	$799.36M	$728.84M	$670.00M	$621.33M	$699.61M	$967.46M
Current Liabilities	$37.05M	$32.52M	$32.60M	$25.58M	$29.75M	$50.80M
Total Debt	$47.16M	$34.18M	$33.33M	$32.46M	$31.57M	$30.66M
Total Liabilities	$78.28M	$63.18M	$62.29M	$54.27M	$57.43M	$77.45M
Retained Earnings	-$1.82B	-$1.89B	-$1.96B	-$2.01B	-$2.09B	-$2.17B
Shareholders' Equity	$721.08M	$665.66M	$607.71M	$567.06M	$642.18M	$890.01M
Working Capital	$702.61M	$647.87M	$591.41M	$552.70M	$628.71M	$877.28M

RLAY Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$73.21M	-$55.26M	-$62.12M	-$44.87M	-$51.11M	-$54.11M
Capital Expenditure	-$384.00K	-$26.00K	—	-$1.00K	—	—
Free Cash Flow	-$73.59M	-$55.29M	-$62.12M	-$44.87M	-$51.11M	-$54.11M
Depreciation & Amortisation	$1.21M	$1.00M	$748.00K	$599.00K	$504.00K	$360.00K
Stock-Based Compensation	$19.32M	$14.50M	$15.53M	$13.07M	$10.54M	$9.18M
Investing Cash Flow	$42.47M	$75.15M	$39.73M	$35.46M	$32.90M	-$353.03M
Financing Cash Flow	$0.00	$653.00K	$17.00K	$934.00K	$138.78M	$323.74M
Net Change in Cash	-$30.75M	$20.54M	-$22.38M	-$8.47M	$120.57M	-$83.40M

Market Snapshot

About

Relay Therapeutics is a clinical-stage precision medicine company focused on transforming drug discovery through computational and experimental technologies. The company uses its Dynamo platform combining computational chemistry, structural biology, and biochemistry to design small molecule therapies for cancer and genetic diseases. Relay has a pipeline of precision medicines targeting proteins with mutations that cause disease.